Serum concentrations of lamotrigine in epileptic patients: The influence of dose and comedication

Therapeutic Drug Monitoring

Volumn 18, Issue 5, 1996, Pages 523-531

  May, Theodor W ^a,b   Rambeck, Bernhard ^a   Jürgens, Uwe ^a  

^a Gesell für Epilepsieforschung ^*  (Germany)

^b Biochemisches Labor   (Germany)

Author keywords

Carbamazepine; Drug interactions; Lamotrigine; Level to dose relationship; Phenobarbital; Phenytoin; Valproic acid

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ADULT; AGE FACTORS; ANTICONVULSANTS; BODY WEIGHT; CARBAMAZEPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PHENOBARBITAL; PHENYTOIN; SEX FACTORS; TRIAZINES; VALPROIC ACID;

EID: 0029759838     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199610000-00001     Document Type: Article

References (45)

1. Goa KL, Ross SR, Chrisp P. Lamotrigine: a review of its pharmacological properties and clinical efficacy in epilepsy. Drugs 1993;46:152-76.
2. Messenheimer JA. Lamotrigine. Clin Neuropharmacol 1994;17:548-59.
3. Pellock JM. The clinical efficacy of lamotrigine as an antiepileptic drug. Neurology 1994;44(suppl 8):29-35.
4. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet 1995;354:476-9.
5. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987; 42:535-41.
6. Miller AA, Sawyer DA, Roth B, et al. Lamotrigine. In: Meldrum BS, Porter RJ. eds. New anticonvulsant drugs. London: John Libbey, 1986:165-77.
7. Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993;25:433-43
8. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
9. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
10. Ramsay RE, Pellock JM, Garnett WR, et al. Pharmacokinetics and safety of lamotrigine (lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
11. Yuen AWC, Land G, Weatherley BC, Peck AW. Sodium valproate inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-3.
12. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
13. Risner ME. Multicenter, double-blind, placebo-controlled, add-on, cross-over study of lamotrigine in epileptic outpatients with partial seizures. Epilepsia 1990;31: 619-20.
14. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
15. Loiseau P, Yuen AWC, Duche B, Menager T, Arnebes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
16. Schmidt D, Krämer G. The new anticonvulsant drugs: implications for avoidance of adverse effects. Drug Safety 1994;11:422-31.
17. Cohen AF, Ashby L, Crowley D, Land G, Peck AW, Miller AA. Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam. Br J Clin Pharmacol 1985;20:619-29.
18. Jawad S, Oxley J, Yuen WC, Richens A. The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy. Br J Clin Pharmacol 1986;22:191-3.
19. Brodie MJ. Lamotrigine. Lancet 1992;339:1397-400.
20. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-9.
21. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994;35:359-67.
22. Jürgens U. Alkylamine/phosphoric acid as a universal buffer system for basic and acidic mobile phases in HPLC. J Liquid Chromatogr 1988;11:1925-40.
23. Jürgens U, Meijer JWA, Land GS. An investigation into alternative HPLC methods to measure plasma lamotrigine. Presented at the 11th Symposium on Column Liquid Chromatography, Amsterdam, 1987.
24. Jürgens U. Simultaneous determination of zonisamide and nine other anti-epileptic drugs and metabolites in serum. J Chromatogr 1987;385:223-40.
25. Draper NR, Smith H. Applied regression analysis. New York: Wiley, 1966.
26. Rambeck B, May T, Jürgens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1987;9:298-303.
27. Norusis MJ. SPSS for Windows. Chicago: SPSS Inc., 1993.
28. Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991;32(suppl 2):9-12.
29. Messenheimer J, Ramsay RE, Willmore LJ, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, cross-over trial. Epilepsia 1994; 35:133-21.
30. Richens A. Pharmacokinetics of lamotrigine. In: Richens A, ed. Clinical update on lamotrigine: a novel antiepileptic agent. Kent: Wells Medical Limited, 1992:21-7.
31. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharm Med 1991;1:121-8.
32. Battino D, Buti D, Croci D, et al. Lamotrigine in resistant childhood epilepsy. Neuropediatrics 1993;24:332-6.
33. Alving J. Case of severe acute intoxication with oxcarbazepine combined with lamotrigine. Epilepsia 1994;35(suppl 7):72.
34. Reutens DC, Duncan JS, Patsalos PN. Disabling tremor after lamotrigine with sodium valproate. Lancet 1993;342: 185-6.
35. Ferrie CD, Panayiotopoulos CP. Therapeutic interaction of lamotrigine with sodium valproate in intractable myoclonic epilepsy. Seizure 1994;3:157-9.
36. Panayiotopoulos CP, Ferrie CD, Knott C, Robinson RO. Interaction of lamotrigine with sodium valproate. Lancet 1993;341:445.
37. Pisani F, Russo M, Trio R, et al. Lamotrigine-valproate comedication in refractory partial seizures: a report of six cases. Epilepsia 1993(suppl 2);34:159.
38. Zagnoni PG, Giubergia S. Lamotrigine and phenytoin: a possible negative interaction. In: Stefan H, Canger R, Spiel G, eds. Epilepsie 93. Berlin: Deutsche Sektion der Int. Liga gegen Epilepsie, 1994:634-7.
39. Mikati MA, Schachter SC, Schomer DL, et al. Long-term tolerability, pharmacokinetics and preliminary efficacy study of lamotrigine in patients with resistant partial seizures. Clin Neuropharmacol 1989;12:312-21.
40. Binnie CD, Debets RMC, Engelsman M, et al. Double-blind crossover trail of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989:4:222-9.
41. Schapel GJ, Beran RG, Vajda FJE, et al. Double-blind, placebo controlled, crossover study of lamotrigine in treatment resistant partial seizures. J Neural Neurosurg Psychiatry 1993;56:448-53.
42. Cocito L, Maffini M, Loeb C. Long-term observation on the clinical use of lamotrigine as add-on drug in patients with epilepsy. Epilepsy Res 1994;19:123-7.
43. Matsua F, Bergen D, Faught E, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
44. Stolarek I, Blacklaw J, Forrest G, Brodie MJ. Vigabatrin and lamotrigine in refractory epilepsy. J Neurol Neurosurg Psychiatry 1994;57:921-4.
45. Betts T, Goodwin G, Withers RM, Yuen AWC. Human safety of lamotrigine. Epilepsia 1991;32(suppl 2):17-21.